Erasca, Inc.
San Diego, CA, US· latest recorded location
Erasca, Inc. is named on 2 US grants and 26 published applications in this corpus. Its most frequent classification is A61P (Therapeutic uses of medicines).
- Granted patents
- 2
- Published applications
- 26
- Inventors
- 38
- Granted in 2026 so far
- 0
- Most recent grant
- 10 Dec 2024
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2022 | 0 | 1 |
| 2023 | 1 | 3 |
| 2024 | 1 | 14 |
| 2025 | 0 | 5 |
| 2026 | 0 | 3 |
By publication year. 2026 runs to 8 Oct.
Technology areas
Share of 28 documents
- A61PTherapeutic uses of medicines28
- A61KMedicines and medical preparations20
- C07DHeterocyclic compounds14
- C07KPeptides5
- C07BGeneral methods of organic chemistry3
- C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen1
- G01NInvestigating or analysing materials by determining their chemical or physical properties1
Recent patents
- Tricyclic pyridones and pyrimidones10 Dec 2024US 12,162,893 B2
- Tricyclic pyridones and pyrimidones19 Dec 2023US 11,845,761 B2
- Ras and prmt5 inhibitors combination therapy17 Sep 2026US 2026/0272921 A1
- Kras inhibitors6 Aug 2026US 2026/0224589 A1
- Raf inhibitor and kras g12c inhibitor combination therapy30 Jul 2026US 2026/0216199 A1
- Tricyclic pyridones and pyrimidones9 Oct 2025US 2025/0313577 A1
- Combination therapies for the treatment of cancer19 Jun 2025US 2025/0195533 A1
Most cited
By later US patents
None of its patents has been cited by a later US patent yet.